Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2003

Study Completion Date

January 31, 2009

Conditions
Lymphoma
Interventions
BIOLOGICAL

autologous immunoglobulin idiotype-KLH conjugate vaccine

BIOLOGICAL

sargramostim

Trial Locations (11)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

46202

Indiana University Cancer Center, Indianapolis

60612

Rush Cancer Institute at Rush University Medical Center, Chicago

63110

Siteman Cancer Center at Barnes-Jewish Hospital, St Louis

94305-5151

Stanford Cancer Center at Stanford University Medical Center, Stanford

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

68198-7680

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha

97201-3098

Cancer Institute at Oregon Health and Science University, Portland

T6G 1Z2

Cross Cancer Institute at University of Alberta, Edmonton

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto

Sponsors
All Listed Sponsors
lead

Genitope Corporation

INDUSTRY